<DOC>
	<DOCNO>NCT01520285</DOCNO>
	<brief_summary>This study compare Felodipine sustained-release tablet , Lercanidipine hydrochloride tablet ( Zanidip® ) treatment patient mild-to-moderate primary hypertension investigate influence patient ' heart rate blood pressure variability .</brief_summary>
	<brief_title>Compare Effects Lercanidipine Hydrochloride Tablet ( Zanidip® ) Felodipine Sustained-Release Tablet Hypertension</brief_title>
	<detailed_description>The study design multicenter , randomize , open-label , parallel-group active control clinical study . The ratio test group ( lercanidipine group ) control group ( felodipine group ) 1:1 . The study period last 8 week , include 0-2 week run-in period 6 week treatment period . There 5 visit : run-in period ( V1 ) , baseline ( V2 ) , 2 week treatment ( V3 ) , 4 week treatment ( V4 ) 6 week treatment ( V5 ) . There 2 week run-in period , patient start continuous record data self-measuring blood pressure heart rate 1 week ( least 5days ) randomize V2 . Patients antihypertensive treatment discontinue antihypertensive treatment le 1 week need discontinue treatment 1week start trial ; patient never receive antihypertensive drug patient discontinue antihypertensive treatment one week directly enter treatment period . In V2 , investigator confirm patient meet inclusion/exclusion criterion , eligible patient divide group random , rest need drop-out trial . In day randomization , patient take drug . After randomization , patient give study drug , take take once-daily dose study drug 07:00-09:00 ( except day visit ) . During treatment , visit every 2 week , visit patient need get study drug next two week , totally 3 time . In V3 V4 , patient ' mean DBP ≥ 90 mm Hg , dose double , twice day ( 07:00- 09:00 morning 16:00-18:00 afternoon ) , otherwise , dosage change . From day begin administration study drug , patient measure BP HR every day electronic sphygmomanometer get morning go bed . And patient record data blood pressure heart rate record card . 2 3 minute wait measure least 12 significant date consecutive 3 day . In every visit , investigator collect data patient 's self-measuring blood pressure , give new record form self-measuring blood pressure patient .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Felodipine</mesh_term>
	<mesh_term>Lercanidipine</mesh_term>
	<criteria>Study population patient mildtomoderate primary hypertension . The diagnosis patient accordance diagnostic criterion Chinese Guidelines Hypertension Prevention Treatment ( 2010 ) . Patients meet follow criterion enrol study : 1 . Male female patient , age 1875 year ; 2 . Mildtomoderate primary hypertension ; 3 . 90mmHg ≤ DBP &lt; 110 mmHg SBP &lt; 180mmHg ; 4 . Patient 's 24h mean blood pressure ( measure ABPM ) &gt; 130/80mmHg ; 5 . Patient sign informed consent form ; 1 . Secondary hypertension ; 2 . Severe hypertension antihypertensive drug unable discontinue ; 3 . History heart failure record LVEF &lt; 40 % , cardiomyopathy valvular heart disease ; 4 . Severe arrhythmia , include arrhythmia , atrial fibrillation , atrial flutter , ventricular tachycardia , advance atrioventricular block sick sinus syndrome ; 5 . History myocardial infarction unstable angina past three month ; 6 . Type I diabetes ; 7 . Type II diabetes , fast bloodglucose ≥ 11.1mmol/L ; 8 . ALT AST ≥ 1.5 time upper limit reference value ; 9 . Abnormal thyroid function ( hyperthyroidism hypothyroidism ) ; 10 . Acute chronic renal insufficiency ( serum creatinine male patient &gt; 176.8 μmol/L female patient &gt; 159.12μmol/L ) ; 11 . Patient suffers anxiety depression ; 12 . Mental disease senile dementia ; 13 . Hypersensitivity calcium channel blocker ; 14 . Pregnancy , lactation ; woman childbearing age use hormonal contraception , perimenopause woman receive hormone treatment ; 15 . History drug alcohol abuse within two year prior enrollment ; 16 . Concomitant administration follow CYP3A4 strong inhibitor : ketoconazole , itraconazole , nefazodone , triacetyloleandomycin , clarithromycin , ritonavir , nelfinavir . Or CYP3A4 inhibitor : erythromycin , verapamil , saquinavir , fluconazole ; inducer drugmetabolizing enzyme liver ( phenytoin , carbamazepine , rifampicin barbiturate ) ; 17 . Patient suffer cerebrovascular accident , severe trauma undergone major operation ; 18 . BMI ≥ 30 kg/m2 ; 19 . Participation clinical trial past three month ; 20 . Investigator judge patient unsuitable participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>hypertension</keyword>
	<keyword>Blood pressure decrease</keyword>
	<keyword>efficacy</keyword>
</DOC>